NORTHBUD Amends Licence Application to Add 500K SQ. FT. of Outdoor Cultivation Area and Provides a Corporate Update
Momentum Public Relations
Press Release: December 20, 2018
North Bud Farms Inc.(CSE: NBUD) (“NORTHBUD” or the “Company”) announced the amendment of its licence application to add 500K SQ. FT. of outdoor cultivation area and provides shareholders with a corporate update on the progress of the corporation and status on its various activities.
Construction of our Cannabis Production Facility in Low, Quebec:
The construction of NORTHBUD’s cultivation facility is progressing on schedule and on budget. The building is soon to be completely enclosed and ready for the next phase in construction. Please see our website www.northbud.com/blog for videos, photos and ongoing updates.
Request for Outdoor Cultivation License:
NORTHBUD is pursuing a standard cultivation licence under The Cannabis Act after acquiring a confirmation of readiness stage ACMPR licence application in early 2018.
The NORTHBUD production facility is located on a 95-acre parcel of farmland in rural Quebec. Under the new regulations, licenced producers can cultivate outdoors. In collaboration with Cannabis Compliance Inc. NORTHBUD will be amending its application to include a 1000 x 500ft outdoor cultivation area. We anticipate this outdoor production footprint to be operational in the spring of 2020 pending the required approvals by Health Canada. NORTHBUD expects to begin implementation of the required infrastructure in Q2 2019 after completion of our 25k sq. ft. indoor production facility that is currently under construction.
Implementation of this additional low-cost production footprint will provide NORTHBUD a unique platform to cultivate both premium quality dried flower as well as low cost commodity grade organic biomass to be transformed into food and pharma grade inputs. This will position NORTHBUD to capitalize on the highest margin market segments.
As the consumer market develops, we believe our diverse centralized infrastructure will provide NORTHBUD a solid, low cost, high quality cannabis supply, which will serve as the core of our products and brand moving forward.
The Gatineau valley has traditionally been a fertile area for outdoor cannabis cultivation with a growing season that typically occurs between mid June and early October. NORTHBUD will be engaging local legacy cultivators to acquire genetics with a track record of success in this particular climate. Our outdoor cultivation will follow international GAP (good agricultural practices) with the drying, trimming and packaging to be done in accordance with GMP standards inside our state-of-the-art custom designed cultivation facility.
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a licence under The Cannabis Act. North Bud Farms Inc. is constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms Inc. will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms Inc.’s final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
investors@northbud.com
- Published in Marijuana, Medical Marijuana, News Home, NorthBud
US Congress Backing of Farm Bill Will ‘Blow Off the Barn Doors Restricting the Hemp Industry’ Says Crop CEO
Momentum Public Relations
Press Release: December 12, 2018
CROP Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) (“CROP”). CROP CEO, Michael Yorke, says the US Farm Bill, so pivotal to the future of the hemp-CBD and cannabis industry, has advanced to within a hair’s breadth of becoming law.
Yesterday the Senate voted overwhelmingly in an 87-to-13 vote to approve the $867 billion farm bill. The legislation now heads to the House, where it is also expected to pass. The breakthrough came after lawmakers worked out a House-Senate compromise earlier this month.
“President Trump expressed his support yesterday as well, so we are not anticipating any further hiccups. Once he signs it into law, billions of dollars in subsidies will flow to farmers, but, from our perspective of course, it is the legalization of hemp which will blow off the political barn doors that have been restricting our industry.
“There is no bigger event than this for the CBD industry. It has been a long time coming and the ramifications are enormous for the USA which is home to some of the best Hemp-CBD genetics in the World.
“CBD, which is expected to grow into a $22 billion industry by 2022, has been stigmatized unfairly for far too long. Now that will all drift rapidly away into oblivion as this industry forges ahead and brings so much benefit to society,” continued Yorke.
On December 4th., CROP announced its 49% owned subsidiary Elite Ventures had leased an additional 250 acres in Nevada taking the company’s 2019 state holdings to 2,115 acres with 1,350 acres already under pivot irrigation for hemp CBD production.
“We are planning to stay well ahead of the curve on hemp and its products as all indications are that this sector alone will prove far more vigorous than was initially forecast,” concluded Yorke.
About CROP
Crop is publicly listed on the CSE and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is focused on cannabis branding and real estate assets. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 2,115 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Business, CROP Infrastructure, hemp, Marijuana, Medical Marijuana, News Home
Tetra Bio-Pharma Confirms Agreements With Multiple Suppliers
Momentum Public Relations
Press Release: December 11, 2018
Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF) a leader in cannabinoid-based drug discovery and development confirms its non-exclusive supply agreement for GMP-Grade THC with U.S.-based Rhodes Technologies Inc. The supply will be used for several drug development activities including Tetra’s cannabinoid-derived products PPP002, PPP003, and PPP004, as well as for discovery phase projects. This is additional to having a supply agreement with True North Cannabis Inc. for CBD from hemp which was necessary to meeting the demand associated with the Genacol Corporation transaction.
“With a robust development pipeline, it is essential for Tetra to have a reliable, API supply to support our expanding needs and avoid product shortages,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “Our agreement with Rhodes is predicated on their long history and expertise in the production and sale of active chemical ingredients, particularly in the area of pain management. In terms of CBD, our suppliers are selected based on their ability to provide us with both quality (GMP Pharmaceutical Grade) and volume. Tetra is always mindful of the need to have consistent supply as well as back-ups for each of the products under development.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma in Process of Filing Patent Application Exceeding its Data Protection Initial Assumption for its PPP001
Momentum Public Relations
Press Release: December 06, 2018
Tetra Bio-Pharma Inc (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it is in process of filing a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that allows for patent protection.
“This patent application, if granted, would provide Tetra with full protection of its PPP001 prescription drug product. This will put PPP001 in the same category as any other innovative prescription drug,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “We recognize the inherent value of our intellectual property and the necessity to seek appropriate patents, to the extent possible, to protect our shareholders’ investments in the Company.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
Investors@tetrabiopharma.com
- Published in Business, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
CROP Begins Development on Outdoor 1,729,000 Square Foot Cannabis Farm in Nevada
Momentum Public Relations
Press Release: December 06, 2018
CROP Infrastructure Corp. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today it is beginning Phase 1 development covering 1,729,000 square feet (40 acres) of outdoor cannabis and 60,000 square feet of greenhouse at its 1,000-acre cannabis farm in Nevada.
It will be protected by an eight-foot-high block wall topped with razor wire and an interior chain link razor wire fence with a guard tower and CCTV. The cost is expected to be $600,000 with final pricing being determined on the greenhouse.
Phase 2 will be to triple the size and output of the farm with the addition of 5,227,200 square feet (120 acres) including an additional 120,000 square feet of greenhouse. Phase 1’s outdoor output is estimated to be roughly 80,000 pounds per year.
The project sits on 1,000 acres of unincorporated land 3.5 hours north of Las Vegas on Highway 95 where outdoor and greenhouse growing is permitted.
The company is now accepting 2019 off take orders and supply agreement requests from processors, distributors and retail outlets.
Michael Yorke, CEO of CROP, states, “CROP will now bring our style of low-cost Cannabis cultivation to Nevada tenants, giving residents and visitors of Nevada a superior product at a lower price and giving processors access to better priced feedstock.”
About CROP
CROP is publicly listed on the CSE and trades under the symbol “CROP” and in the U.S. under the symbol “CRXPF”. CROP is focused on cannabis branding and real estate assets. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 2,115 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, U.S. and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the Nevada Project; the technological effects of Nevada Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke
CEO and Director
E-mail: info@cropcorp.com
Phone: (604)484-4206
Website: http://www.cropcorp.com
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home
CROP Increases Nevada Land Position for Hemp CBD to 2,115 Acres in Anticipation of Hemp Provisions in Farm Bill Passing
Momentum Public Relations
Press Release: December 04, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (CSE: CROP.CN) (OTC: CRXPF) (Frankfurt: 2FR) announced today its 49% owned subsidiary Elite Ventures has leased an additional 250 acres in Nevada taking the company’s 2019 state holdings to 2,115 acres with 1,350 acres already under pivot irrigation.
With the new US Farm Bill now including critical provisions on hemp, CROP already announced on October 23rd, a 3-year, 1,500,000 pound, $18.0–$28.0 MM USD per year CBD biomass supply agreement in the US (depending on CBD content) and is now focusing on allocating 2019 CBD Isolate supply agreements both domestically and internationally.
Cannabis industry analysts, The Brightfield Group, estimate the hemp-CBD market alone could reach $22-billion by 2022.
CROP CEO, Michael Yorke, stated: “As you can see from our summary of the significant points of this bill, the positive impact on the industry in the US will be enormous. It will show the world that our industry is here to stay and will expand considerably, not just domestically but as we begin to work with customers globally.”
About the Farm Bill of 2018,Excerpt from High Times Magazine
In a move that marks a major shift in U.S. agriculture and drug policy, House and Senate lawmakers have come to an agreement over the status of industrial hemp in H.R. 2, The Agriculture Improvement Act of 2018. Known as the 2018 Farm Bill, H.R. 2 includes far-reaching provisions that lift the ban on hemp, authorize hemp production and research and amend the Controlled Substances Act. Furthermore, the reconciled version of the Farm Bill paves the way for the federal regulation of hemp-derivedcannabidiol (CBD)extracts. For hemp CBD consumers, that would mean both better product consistency and quality and an end to the legal ambiguity of hemp CBD.
2018 Farm Bill Exempts Hemp from Controlled Substances Act
Perhaps the most striking element of the Farm Bill, however, is how it amends the Controlled Substances Act. Since 1970, hemp has been listed as a Schedule I controlled substance. But H.R. 2 would exempt commercial hemp from the Schedule I classification, so long as products meet one requirement. Hemp products must contain no more than 0.3 percent of delta-9-tetrahydrocannabinol, akaTHC, by dry weight.
Several key consequences stem from this change. First, it effectively lifts the prohibition on all the other cannabinoids that can be sourcedfrom hemp, likeCBDV,CBN, CBG. Research continues to demonstrate the immense therapeutic potential of suchrare cannabinoids. Under the Farm Bill‘s provisions, any part of the hemp plant, from its seeds to its extracts, acids, salts, and isomers are exempt from the Controlled Substances Act.
The full H.R. 2 farm bill can be seen here: https://www.congress.gov/bill/115th-congress/house-bill/2/text
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the Nevada Project; the technological effects of Nevada Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Phone: +1-604-484-4206
Website: www.cropcorp.com
SOURCE CROP INFRASTRUCTURE CORP.
- Published in Business, CROP Infrastructure, Marijuana, Medical Marijuana, News Home
Tetra Bio-Pharma Convenes First National Medical Advisory Board
Momentum Public Relations
Press Release: December 04, 2018
Tetra Bio-Pharma Inc (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), – announced that it held its first National Advisory Board meeting in Toronto, on November 30, 2018 as a platform to validate their drug development and commercial programs. Physicians from diverse medical specialties, including oncology, palliative care, as well as mental health, family medicine and anaesthesiology had the opportunity to discuss the place for cannabinoid derived medicines as a potential therapeutic option in pain management. There was a genuine interest into evidence-based medicine to further substantiate their position on cannabinoid derived therapies.
“I am confident that this will be the first of many transparent and collaborative exchanges that Tetra organizes with physicians as we seek to bring cannabinoid-derived medicines into our healthcare system,” said Steeve Neron, Senior Vice-President, Marketing and Medical Affairs. “The level of engagement was encouraging and leads me to believe that physicians are open to consider cannabinoids as a drug they can incorporate into their practice, but without the evidence, they simply will not. This is where Tetra’s scientific data will be invaluable.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Natural Health Will Deliver 20 containers of Hemp Energy Drink to Meet Consumer Demand
Momentum Public Relations
Press Release: December 03, 2018
Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink, the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country.
|
Canadian consumers appreciate the qualities of Hemp Energy Drink (www.hempenergydrink.ca) that contains fewer calories and more natural ingredients than other energy drinks, and the product will be available soon everywhere in Canada in three flavors: classic, mango and raspberry.
“We are very pleased with the consumer interest for the Hemp Energy Drink since its launch. Through the agreements we have with our distribution partners, their drive and the strategy we are implementing, Canadians will soon be able to appreciate the three flavors of our cool, fresh, light, natural and 100% legal beverage,” said Richard Giguère, CEO of Tetra Natural Health.
“This 20-container delivery combined with the deployment of our distribution strategy represents an important step in our market development plan for this product over the next year. Thanks to the characteristics of our energy drink and its nutritional elements, we are confident that the Hemp Energy Drink will generate a continued enthusiasm among consumers across Canada,” added Richard Giguère.
Guy Chamberland, President and CEO of Tetra Bio-Pharma stated, “With its Hemp Energy Drink business, Tetra Natural Health will allow the corporation to achieve significant orders and sales over the coming year. These orders demonstrate that the new team has established a viable natural health and wellness product business that will translate into significant revenues for the coming fiscal year, starting in Q1 2019.”
About Tetra Natural Health
Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For more information, please contact:
Richard Giguère
CEO
Tetra Natural Health
T 348-899-7575 ext.210
rgiguere@tetrabiopharma.com
- Published in Business, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Growpacker Inc. Announces Partnership with InterContinental Beverage Capital
Momentum Public Relations
Press Release: November 30, 2018
Growpacker Inc. (“Growpacker” or the “Company”), a contract manufacturer of various THC and CBD infused edibles and beverages in the United States, is pleased to announce it has signed a partnership agreement with InterContinental Beverage Capital (“IBC”).
IBC is a New York-based advisory and merchant banking firm with representative offices in Atlanta, Boca Raton, Los Angeles, and Lugano, Switzerland. The firm’s founders and partners have held top executive positions with multiple beverage companies, including MillerCoors, Coca-Cola, Red Bull, Diageo, and Cadbury Schweppes. IBC has expanded its footprint and influence in the cannabis infused beverage sector over the last year with the spread of the medical and recreational cannabis sector in the U.S.
The term of the agreement will allow Growpacker to leverage IBC for key market development services for its clients entering the THC & CBD infused beverage sector. Services will include brand development, business strategy & planning, advertising, and merchandising. IBC will have the opportunity to leverage Growpacker for turnkey formulation, packaging, manufacturing, and distribution of THC & CBD infused beverages for their growing list of clients wishing to enter the California market.
Growpacker has been ramping up its strategic partnerships across America to build the most comprehensive, experienced, and collaborative team possible in all ancillary sides of the cannabis industry. The company believes that the beverage and edible categories are primed for explosive growth over the coming years, and intends to align itself with powerful visionaries and disruptors who share the same vision.
“We are thrilled to be working with such experienced industry experts. Our company’s alignment with other best of breed companies and individuals will assist in hyper accelerating our near and long term goals”, said Stephen Boyd, Founder & CEO of Growpacker.
About Growpacker
Growpacker Inc. is a Canadian based company, which through its American interest in GP Holdings LLC, is engaged in expanding the ancillary side of the California cannabis industry. The company offers local and international brands key services, such as formulation, manufacturing, co-packing, and distribution for THC & CBD infused products.
- Published in Business, growpacker, Marijuana, Medical Marijuana, News Home
CROP Farm Signs California Processing and Retail Distribution Deals
Momentum Public Relations
Press Release: November 29, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today it has signed a toll processing agreement with a manufacturing company that will produce oils, crumbles and distillates for sale in to the California market.
The raw material will be finished cannabis from CROP’s Humboldt County farm where the cannabis is awaiting sale, being trimmed or drying. The farm is currently flowering 10,000 sqft of canopy for a late stage harvest and is working on the permitting for its 2019 expansion including a proposed 30,000 sq ft automated greenhouse facility.
In addition, a distribution agreement is now in place for the cannabis which will be sold under the company’s Hempire brand for estimated gross revenue of approximately $1,600 per pound of flower. The farm has allocated 750lbs of inventory to be sold under the Hempire brand.
The distributor has offices in Oakland and Orange County. Their distribution network consists of approximately 350 licensed cannabis stores across California.
CROP CEO, Michael Yorke, stated: “Progress is continuing on becoming fully vertically integrated with self-serving Emerald Heights retail application. Processing and distribution are key agreements in getting our product onto hundreds of potential retail shelves. CROP’s core goal is maximizing its return on investment from tenant 2018 production, while preparing and building relationships for an exciting 2019.”
About CROP
CROP is publicly listed on the CSE and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is focused on cannabis branding and real estate assets. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the California Project; the technological effects of California Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: +1(604)484-4206
- Published in CROP Infrastructure, Marijuana, Medical Marijuana, News Home